Steroids and COVID-19 : We Need a Precision Approach, Not One Size Fits All
© The Author(s) 2020..
COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
---|---|
Enthalten in: |
Infectious diseases and therapy - (2020) vom: 16. Sept., Seite 1-5 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Waterer, Grant W [VerfasserIn] |
---|
Links: |
---|
Themen: |
ARDS |
---|
Anmerkungen: |
Date Revised 22.02.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1007/s40121-020-00338-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315247231 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM315247231 | ||
003 | DE-627 | ||
005 | 20240229142852.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40121-020-00338-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1303.xml |
035 | |a (DE-627)NLM315247231 | ||
035 | |a (NLM)32953385 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Waterer, Grant W |e verfasserin |4 aut | |
245 | 1 | 0 | |a Steroids and COVID-19 |b We Need a Precision Approach, Not One Size Fits All |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 22.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © The Author(s) 2020. | ||
520 | |a COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ARDS | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a Covid-19 | |
650 | 4 | |a Pneumonia | |
650 | 4 | |a Precision medicine | |
650 | 4 | |a RCT | |
650 | 4 | |a SARS | |
650 | 4 | |a Therapy | |
700 | 1 | |a Rello, Jordi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g (2020) vom: 16. Sept., Seite 1-5 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
773 | 1 | 8 | |g year:2020 |g day:16 |g month:09 |g pages:1-5 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-020-00338-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2020 |b 16 |c 09 |h 1-5 |